Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.

ABSTRACT:

Background

There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer.

Methods

We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrated Research Database (HIRD), a longitudinal claims database of commercial health plan members in the United States. The historical comparator cohort comprised patients initiating fulvestrant monotherapy from January 2011 to January 2015. Propensity score matching and Cox regression were used to estimate hazard ratios for various safety events. For acute liver injury (ALI), additional analyses and medical record validation were conducted.

Results

There were 2445 patients who in

SUBMITTER: Beachler DC 

PROVIDER: S-EPMC7831235 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature